Study to Assess Safety, Tolerability and Efficacy of SC Administered MBL949 in Obese Participants With or Without T2DM

The study comprised a screening/baseline period of up to 35 days (5 weeks), a 14-week treatment period in which participants were administered MBL949 or placebo at 8 biweekly intervals starting on Day 1 and a 10-week follow-up period. Participants were to be enrolled to: * MBL949 Arm 1, MBL949 Arm 2 and placebo in a 1:1:1 ratio * MBL949 Arm 3, MBL949 Arm 4 and placebo in a 1:1:1 ratio * If MBL949 Arm 1 was tolerated, MBL949 Arm 5 was enrolled with a 2:1 ratio (MBL:placebo) within each stratum.